Ugeskr Læger 2016;178:V08150648
Adjuvant medical treatment for patients with locoregional recurrence of breast cancer
There is 10-30% risk of developing isolated locoregional recurrence (ILRR) after mastectomy for primary breast cancer. Currently, there is no standard treatment for ILRR and therefore patients with ILRR cause an oncological task. This review investigates existing literature concerning relevant randomized trials of adjuvant medical treatment with chemotherapy, anti-hormonal and anti HER2 treatments for patients radically treated for ILRR. Certain groups of patients may benefit from adjuvant systemic treatment. However larger randomized trials are needed.